1.	Phase II Randomized Study Comparing Immunologic Responses of Stage II and III Colorectal Cancer Patients on Adjuvant Therapy Treated with 3H1 Anti-Idiotype Monoclonal Antibody Mixed with Sargramostim Versus 3H1 Anti-Idiotype Monoclonal Antibody Alum Precipitate Mixed with Sargramostim (Summary Last Modified 01/2000) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: UKMC-95GI24CB, NCI-H97-1184
2.	Phase II Study of Vaccine Therapy With Tumor-Specific Mutated Ras Peptides in Combination With Interleukin-2 and/or Sargramostim (GM-CSF) in Adults With Metastatic Solid Tumors Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-97-C-0141F, NCI-T96-0078, T96-0078, NCT00019331
3.	Phase I Study of Carcinoembryonic Antigen Peptide-1 (CAP) and DetoxPC for Adenocarcinomas of the Gastrointestinal Tract, Breast, and Lung (Summary Last Modified 09/1999) Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-96-C-0139, NCI-NMOB-9305, NCI-T96-0058N, T96-0058
4.	Phase I Study of Recombinant Carcinoembryonic Antigen (CEA) Vaccinia Virus Vaccine With Post Vaccination CEA Peptide Challenge in Patients With Malignant Solid Tumors (Summary Last Modified 04/2000) Phase: Phase I Type: Treatment Status: Completed Age: over 18 Sponsor: NCI Protocol IDs: MUSC-6124, NCI-T95-0044, T95-0044
5.	Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage IIIA Non-small Cell Lung Cancer or With Stage I or Stage II Mesothelioma Phase: Phase I Type: Treatment Status: Completed Age: 20 to 70 Sponsor: Other Protocol IDs: CDR0000067177, RPCI-DS-96-25, NCI-G99-1551, NCT00003974